Ceraxon solution for i/m and i/v injection

Valsts: Armēnija

Valoda: angļu

Klimata pārmaiņas: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

Aktīvā sastāvdaļa:

citicoline (citicoline sodium)

Pieejams no:

Ferrer International

ATĶ kods:

N06BX06

SNN (starptautisko nepatentēto nosaukumu):

citicoline (citicoline sodium)

Deva:

500mg/4ml

Zāļu forma:

solution for i/m and i/v injection

Vienības iepakojumā:

(5) ampoules 4ml

Receptes veids:

Prescription

Autorizācija statuss:

Registered

Autorizācija datums:

2018-12-27

Produkta apraksts

SUMMARY PRODUCT CHARACTERISTICS
1.
NAME OF THE MEDICINAL PRODUCT
CERAXON 500 mg solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
CERAXON 500 mg solution for injection is supplied in 4 ml glass
ampoules. The active ingredient is
Cticoline sodium 522.5mg (equal to the 500mg Citicoline)
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Solution for injection.
CERAXON 500 mg solution for injection: Clear and colourless water
solution.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS

Ischemic stroke, acute phase and its neurological sequelae (as a part
of complex therapy)

Rehabilitation period of ischemic and hemorrhagic stroke

Traumatic Brain injury and its neurological sequelae, acute phase (as
a part of complex
therapy) and rehabilitation period

Cognitive and behavioural impairment secondary to chronic vascular and
degenerative cerebral
disorders.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
ADULTS:
The recommended dose is from 500 to 2,000 mg/day, depending on the
severity of the symptoms to be
treated.
It can be administered by intramuscular, slow intravenous route (from
3 to 5 minutes depending on the
administered dose) or in intravenous drop perfusion (dripping speed:
40-60 drops per minute).
THE DOSAGE RECOMMENDATIONS
_The acute phase of Ischemic stroke and Traumatic Brain injury_
:
1000mg every 12 hours from the first day after diagnosis.
,
treatment duration of at least 6 weeks.
It is
possible a transition to the oral forms of Ceraxon 3-5 days after
starting of treatment, if the swallowing
function is not impaired.
_Rehabilitation period of ischemic and hemorrhagic stroke,
rehabilitation period of Traumatic Brain injury, _
_Cognitive and behavioural impairment secondary to chronic vascular
and degenerative cerebral disorders: _
_ _
500-2000mg daily. The dosage and duration of treatment depend on the
severity of symptoms. The oral
forms of Ceraxon can be used also.
See the instructions for preparation in section 6.6.
ELDERLY:
CERAXON does not need any spe